🇺🇸 FDA
Pipeline program

Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

213400

Phase 3 small_molecule active

Quick answer

Niraparib Placebo Tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion for Lung Cancer, Non-Small Cell is a Phase 3 program (small_molecule) at GlaxoSmithKline Biologicals S.A. with 1 ClinicalTrials.gov record(s).

Program details

Company
GlaxoSmithKline Biologicals S.A.
Indication
Lung Cancer, Non-Small Cell
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials